Skip to main content
Premium Trial:

Request an Annual Quote

Russ Smestad, Martin Bedigian

Premium
Mirus Bio President Russ Smestad plans to leave the company after completion of Roche’s planned acquisition of Mirus (see related story, this issue).
 
According to Smestad, he will remain with Mirus through the transition period following the acquisition, but will then leave to pursue other opportunities in the biotechnology field.
 

 
Isis Pharmaceuticals said last week that it has appointed Martin Bedigian as vice president and chief medical officer.
 
In this role, Bedigian will be responsible for all medical aspects of Isis' clinical development programs, the company said.
 
Bedigian previously served as global head of Novartis’ cardiovascular assessment group. He holds an MD from New York Medical College and completed his residency at Emory University.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.